Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Colorectal Neoplasms 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Neoplasm Metastasis 1Liposarcoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Non-small Cell Lung Cancer (NSCLC) 1

Interventions

trametinib 6dabrafenib 6pembrolizumab 5lenvatinib 5Paclitaxel 5Sorafenib 4Radiotherapy, Intensity-Modulated 3Doxorubicin 3pazopanib 2atezolizumab 2aldesleukin 2Taxes 2Radiotherapy 2Nivolumab 2Everolimus 2Bevacizumab 2zimberelimab 1selpercatinib 1sargramostim 1sacituzumab govitecan 1fosbretabulin 1fludarabine 1efatutazone 1cobimetinib 1ceritinib 1cemiplimab 1cabozantinib 1abemaciclib 1Vemurafenib 1Tamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thyroid Carcinoma, Anaplastic × efatutazone × Clear all
NCT02152137 2025-01-27

Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
19 enrolled 13 charts
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡